Neovasc to Participate in H.C. Wainwright & Co. 23rd Annual Global Investment Conference
August 30 2021 - 4:05PM
via NewMediaWire –
Neovasc, Inc. (“Neovasc” or the
“Company”) (NASDAQ,TSX: NVCN) today announced that its management
team will be participating in the 23rd Annual H.C. Wainwright
Global Investment Conference to be held September 13-15, 2021. A
pre-recorded company presentation will be available beginning at
7:00 am EDT on September 13 through the conference website and the
Investor Relations section of the Neovasc website
at https://www.neovasc.com/investors/. The recording will be
archived for 90 days.
About Neovasc Inc.
Neovasc is a specialty medical device
company that develops, manufactures and markets products for the
rapidly growing cardiovascular marketplace. The Company is a leader
in the development of minimally invasive transcatheter mitral valve
replacement technologies, and minimally invasive devices for the
treatment of refractory angina. Its products include the Neovasc
Reducer™, for the treatment of refractory angina, which is not
currently commercially available in the United States (6 U.S.
patients have been treated under Compassionate Use) and has been
commercially available in Europe since 2015, and Tiara™, for the
transcatheter treatment of mitral valve disease, which is currently
under clinical investigation in the United States, Canada, Israel,
and Europe. For more information, visit: www.neovasc.com.
Forward-Looking Statement
Disclaimer
Certain statements in this news
release contain forward-looking statements within the meaning of
the U.S. Private Securities Litigation Reform Act of 1995 and
applicable Canadian securities laws that may not be based on
historical fact. When used herein, the words “expect”,
“anticipate”, “estimate”, “may”, “will”, “should”, “intend,”
“believe”, and similar expressions, are intended to identify
forward-looking statements. Forward-looking statements may involve,
but are not limited to, expectations as to the future growth of the
Company, the expansion of its product range and the growing
cardiovascular marketplace. Forward-looking statements are based on
estimates and assumptions made by the Company in light of its
experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors that the Company believes are appropriate in the
circumstances. Many factors could cause the Company’s actual
results, performance or achievements to differ materially from
those expressed or implied by the forward-looking statements,
including those described in the “Risk Factors” section of the
Company’s Annual Report on Form 20-F and in the Management’s
Discussion and Analysis for the three and six months ended June 30,
2019 (copies of which may be obtained at www.sedar.com or
www.sec.gov). These factors should be considered carefully, and
readers should not place undue reliance on the Company’s
forward-looking statements. The Company has no intention and
undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts
InvestorsMike
CavanaughWestwicke/ICRPhone:
+1.617.877.9641Mike.Cavanaugh@westwicke.com
MediaSean LeousWestwicke/ICRPhone:
+1.646.866.4012Sean.Leous@westwicke.com
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Apr 2023 to Apr 2024